WO2003101482A3 - Liposome vaccine formulations for fin-fish - Google Patents

Liposome vaccine formulations for fin-fish Download PDF

Info

Publication number
WO2003101482A3
WO2003101482A3 PCT/CA2003/000768 CA0300768W WO03101482A3 WO 2003101482 A3 WO2003101482 A3 WO 2003101482A3 CA 0300768 W CA0300768 W CA 0300768W WO 03101482 A3 WO03101482 A3 WO 03101482A3
Authority
WO
WIPO (PCT)
Prior art keywords
fin
fish
vaccine formulations
vaccines
liposome
Prior art date
Application number
PCT/CA2003/000768
Other languages
French (fr)
Other versions
WO2003101482A2 (en
Inventor
Kevin M W Keough
Original Assignee
Genesis Group Inc
Kevin M W Keough
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesis Group Inc, Kevin M W Keough filed Critical Genesis Group Inc
Priority to AU2003229199A priority Critical patent/AU2003229199A1/en
Publication of WO2003101482A2 publication Critical patent/WO2003101482A2/en
Publication of WO2003101482A3 publication Critical patent/WO2003101482A3/en
Priority to NO20045587A priority patent/NO335784B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Liposome vaccine formulations for fin-fish are provided which comprise antigenic material derived from one or more fin-fish pathogen in association with liposomes, and optionally include other therapeutic compounds. The vaccines can be used for immunization and/or therapeutic treatment of fin-fish against infectious and parasitic diseases. The vaccines can result in reduced side effects, such as less adhesions and pigmentation, compared to oil-based vaccine formulations. The present invention also provides methods of preparing and storing the liposome vaccines and methods of administering the vaccine formulation to fin-fish.
PCT/CA2003/000768 2002-05-31 2003-05-30 Liposome vaccine formulations for fin-fish WO2003101482A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003229199A AU2003229199A1 (en) 2002-05-31 2003-05-30 Liposome vaccine formulations for fin-fish
NO20045587A NO335784B1 (en) 2002-05-31 2004-12-22 Liposome vaccine comprising antigenic material from fin-fish pathogens.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38502802P 2002-05-31 2002-05-31
US60/385,028 2002-05-31

Publications (2)

Publication Number Publication Date
WO2003101482A2 WO2003101482A2 (en) 2003-12-11
WO2003101482A3 true WO2003101482A3 (en) 2004-02-05

Family

ID=29712127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/000768 WO2003101482A2 (en) 2002-05-31 2003-05-30 Liposome vaccine formulations for fin-fish

Country Status (3)

Country Link
AU (1) AU2003229199A1 (en)
NO (1) NO335784B1 (en)
WO (1) WO2003101482A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107099496B (en) * 2017-04-25 2021-04-13 中国农业科学院哈尔滨兽医研究所 Recombinant lactic acid bacteria strain for fusion expression of chicken infectious bursal disease virus VP2 protein and salmonella outer membrane protein and application thereof
CN111018955B (en) * 2020-01-06 2021-10-26 济南大学 Polypeptide for inhibiting viral genome RNA replication

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2575156T3 (en) 2004-07-28 2016-06-24 National Research Council Of Canada Recombinant vaccines against caligidae copepods (sea lice) and their antigenic sequences
CN1276076C (en) * 2004-12-14 2006-09-20 华东理工大学 No mark gene deletion deoxidated mutant strain of wild Manhu bacteria and its use
US20100047329A1 (en) * 2006-02-07 2010-02-25 Nippon Biologicals, Inc. Novel Vaccination Carrier
EP2113511A4 (en) 2006-12-22 2010-09-15 Soluciones Biotecnologicas Inn Dna vaccines for fish
ES2321789B1 (en) * 2007-03-02 2010-03-15 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria (Inia) USE OF THE PIL8 + VECTOR TRUCK AS IMMUNO STIMULANT OR ADJUVANT FOR DNA VACCINES IN FISH.
US8343505B2 (en) * 2007-12-04 2013-01-01 Schweitzer Co., Ltd. Subunit vaccine for aquaculture
NO333242B1 (en) * 2008-02-08 2013-04-15 Pharmaq As Composition, medical application and method comprising salmonid alphavirus
NO20200827A1 (en) * 2017-12-26 2020-07-14 Univ Chile Vaccine formulation for fish based on lipid nanovesicles,particularly a proteoliposome or cochleate, with activity against the salmonid rickettsial syndrome (srs)
KR102458429B1 (en) * 2021-03-18 2022-10-26 대한민국 Fish Oral Vaccine Liposomes for preventing viral hemorrhagic septicemia and Preparation Method Thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037100A2 (en) * 1998-12-22 2000-06-29 Dalhousie University Compositions and methods for reducing or preventing fertilization in fish and birds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037100A2 (en) * 1998-12-22 2000-06-29 Dalhousie University Compositions and methods for reducing or preventing fertilization in fish and birds

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
FERNANDEZ-ALONSO M ET AL: "DNA vaccination by immersion and ultrasound to trout viral haemorrhagic septicaemia virus", VACCINE, vol. 19, no. 23-24, 30 April 2001 (2001-04-30), pages 3067 - 3075, XP004234177, ISSN: 0264-410X *
IRIE T ET AL: "Humoral immune response of carp (Cyprinus carpio) induced by oral immunization with liposome-entrapped antigen.", DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, vol. 27, no. 5, May 2003 (2003-05-01), pages 413 - 421, XP002261927, ISSN: 0145-305X *
NAKHLA A ET AL: "Uptake and biodistribution of free and liposomally incorporated lipopolysaccharide of Aeromonas salmonicida administered via different routes to rainbow trout (Oncorhynchus mykiss)", JOURNAL OF LIPOSOME RESEARCH, vol. 4, no. 2, 1994, pages 1029 - 1048, XP000457304, ISSN: 0898-2104 *
NAKHLA A N ET AL: "Incorporation of the lipopolysaccharide and polysaccharide from Aeromonas salmonicida into liposomes", JOURNAL OF LIPOSOME RESEARCH, vol. 6, no. 1, 1996, pages 141 - 154, XP001160908, ISSN: 0898-2104 *
NAKHLA A N ET AL: "Serum anti-LPS antibody production by rainbow trout (Oncorhynchus mykiss) in response to the administration of free and liposomally-incorporated LPS from Aeromonas salmonicida", FISH AND SHELLFISH IMMUNOLOGY, vol. 7, no. 6, 1997, pages 387 - 401, XP002261926, ISSN: 1050-4648 *
POWER C A ET AL: "Uptake and tissue distribution of liposomes after intraperitoneal administration to rainbow trout, Oncorhynchus mykiss (Richardson): a preliminary report", JOURNAL OF FISH DISEASES, vol. 13, no. 4, 1990, pages 329 - 332, XP008024689, ISSN: 0140-7775 *
RODGERS C J: "Immersion vaccination for control of fish furunculosis", DISEASES OF AQUATIC ORGANISMS, vol. 8, no. 1, 6 March 1990 (1990-03-06), pages 69 - 72, XP008024690, ISSN: 0177-5103 *
ROMOEREN K ET AL: "Immersion delivery of plasmid DNA I. A study of the potentials of a liposomal delivery system in rainbow trout (Oncorhynchus mykiss) fry.", JOURNAL OF CONTROLLED RELEASE, vol. 85, no. 1-3, 13 December 2002 (2002-12-13), pages 203 - 213, XP004397779, ISSN: 0168-3659 (ISSN print) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107099496B (en) * 2017-04-25 2021-04-13 中国农业科学院哈尔滨兽医研究所 Recombinant lactic acid bacteria strain for fusion expression of chicken infectious bursal disease virus VP2 protein and salmonella outer membrane protein and application thereof
CN111018955B (en) * 2020-01-06 2021-10-26 济南大学 Polypeptide for inhibiting viral genome RNA replication

Also Published As

Publication number Publication date
NO335784B1 (en) 2015-02-16
AU2003229199A8 (en) 2003-12-19
AU2003229199A1 (en) 2003-12-19
WO2003101482A2 (en) 2003-12-11
NO20045587L (en) 2004-12-22

Similar Documents

Publication Publication Date Title
WO2004064759A3 (en) Use of tryptanthrin compounds for immune potentiation
WO2005016239A3 (en) Molecules enhancing dermal delivery of influenza vaccines
WO2002028422A3 (en) Split enveloped virus preparation for intranasal delivery
WO2002080965A3 (en) Vaccine composition
PL351893A1 (en) Vaccines
WO2007095976A3 (en) Adjuvant in the form of a lipid-modified nucleic acid
WO2001092470A3 (en) Dna expression vectors and methods of use
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
WO2007130493A3 (en) Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
WO2005063201A3 (en) Liposomes and liposomal compositions for vaccination and drug delivery
AU2002254901A1 (en) Influenza vaccine formulations for intradermal delivery
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
WO2005097211A3 (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
GB0109297D0 (en) Vaccine
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
WO2003101482A3 (en) Liposome vaccine formulations for fin-fish
WO2008054535A3 (en) Novel influenza m2 vaccines
WO2010016912A3 (en) Immunotherapeutic compositions for the treatment of alzheimer's disease
WO2002087494A3 (en) Novel vaccine
WO2003059385A3 (en) Hiv vaccine and method of use
WO2005007673A3 (en) Immunogenic peptides
WO2005074460A3 (en) Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
WO2003080111A3 (en) Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
WO2001070265A3 (en) Lipopeptide adjuvants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP